Novadoz Pharmaceuticals, the U.S based sales & marketing affiliate for MSN Labs has received FDA approval for their generic version of Febuxostat 40mg and 80mg tablets. The product is AB rated to the brand Uloric©, marketed by Takeda Pharmaceuticals America. The company has commenced shipping of the product that is available in bottles of 30 tablets. Febuxostat brand and generic sales are trending over $430MIL over the previous 12 months according to recent published sales data.
Febuxostat is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia (elevated levels of uric acid) in adult patients with gout who have a poor response to a maximally titrated dose of Allopurinol, patients intolerant to Allopurinol, and for treatment where Allopurinol is not advisable.
"FDA approval of Febuxostat is the 12th product introduction for the Novadoz label in the first 20 months of our U.S commercialization,” Seshu Akula, Novadoz President North America Generics, said. “Novadoz and the MSN organizations are committed to being part of DAY 1 and DAY 181 product launches, providing high value to our customers, and to the pharmacies and companies in their supply chain. Our vertical integration through MSN, the #1 API supplier in the world, continues to define our success now and in the future. We expect continued success in 2020 with multiple product approvals, including several in the specialty oncology space."